英国QuantuMDx
QuantuMDx集团是一家年轻而充满活力的医疗器械公司开发的手持式和便携式
低成本诊断，基因组测序和蛋白质组平台，能够支持发达国家和发展中国家之间提供个性化的医药。

QuantuMDx Group was founded in early 2008 by Elaine Warburton,
Jonathan O’Halloran and Julian Warburton.
The Company’s humble beginnings began over ten years’ ago in Jonathan’s garage where he re-arranged chemicals, reagents and biological processes and sensed them using computer transistors which provided sufficient proof of principle for his novel nucleic acid sequencing technology. Elaine, using her healthcare background and extensive commercial experience harnessed Jonathan’s technology to develop it into commercially viable and simple to use devices to meet many of today’s health challenges.

QuantuMDx is now leveraging its global network and expertise across many fields and has developed a suite of diagnostic and sequencing bio-chips capable of being assembled into a wealth of low cost but highly accurate handheld devices for the next generation of doctors, health professionals, scientists, vets, military and police.

From our years spent delivering healthcare in hospitals, diagnostics in path labs, negotiating with health funders and bringing medical and genetic innovation into mainstream medicine, we believe we are well placed to understand what doctors, health practitioners, vets, health funders and importantly patients need to effect a successful diagnosis leading to the optimum care pathway.

We continue to undertake extensive research across the globe – from township clinics to state-of-the-art hospitals - to find out exactly what our customers want from our medical devices

QuantuMDx Group is a young and vibrant medical devices company developing hand-held and portable
low cost diagnostic, genomic sequencing & proteomic platforms capable of supporting the delivery of personalised medicine across both developed and developing nations.

Our focus is to develop simple, easy to use devices that not only deliver rapid & accurate - sample to result - medical diagnosis for complex diseases within minutes at the patient’s side, but can integrate with mobile apps for ongoing support and education of patients.

Our first commercial product, due out in 2013, will be the Q-POC™, QuantuMDx’s hand-held point of care platform, with first commercial assays in companion diagnostics and multi-drug resistant infectious disease testing (including TB, HIV and STIs).

Products in development include Q-SEQ™, a portable genomic sequencer, and InVenio™, a whole proteome array.